Renovaro Cube develops a proprietary analytical tool that utilizes machine learning algorithms to analyze genetic data through non-invasive liquid biopsies. This technology enables early cancer detection and personalized treatment selection, improving patient outcomes while minimizing the need for invasive procedures.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer diagnostic methods often rely on invasive procedures or late-stage detection, leading to delayed treatment and poorer patient outcomes. Traditional biopsies can be risky and may not always capture the full heterogeneity of the tumor, while existing non-invasive methods may lack the sensitivity for early detection.
Solution
Renovaro Cube is developing a liquid biopsy platform that uses machine learning algorithms to analyze genetic data from a simple blood draw. This non-invasive approach aims to detect cancer at an earlier stage, enabling timely intervention and personalized treatment strategies. By analyzing circulating tumor DNA (ctDNA) and other biomarkers, the platform provides a comprehensive profile of the tumor's characteristics, including its genetic mutations and potential drug sensitivities. The goal is to improve patient outcomes by minimizing the need for invasive procedures and tailoring treatment plans to the individual's specific cancer profile. The platform also aims to monitor treatment response and detect recurrence, providing clinicians with valuable insights throughout the patient journey.
Target Audience
The primary target audience includes oncologists, pathologists, and healthcare providers involved in cancer diagnostics and treatment, as well as patients at risk of or diagnosed with cancer.
Features
- Non-invasive cancer detection using liquid biopsies (blood samples)
- Machine learning algorithms for analyzing complex genetic data
- Analysis of circulating tumor DNA (ctDNA) and other relevant biomarkers
- Early cancer detection capabilities for timely intervention
- Personalized treatment selection based on individual tumor profiles
- Monitoring of treatment response and detection of recurrence
- Identification of cancer-specific biomarkers